9 7 1 a r t I C l e S Fingolimod, also known as FTY720, is the first orally available therapeutic agent approved for treatment of relapsing-remitting multiple sclerosis, a disorder of the CNS 1 . FTY720, a synthetic analog of sphingosine, is a prototype of immunomodulatory prodrugs that is phosphorylated in vivo to FTY720-phosphate (FTY720-P) by sphingosine kinases (SphKs), especially SphK2, to a mimetic of sphingosine-1-phosphate (S1P). This bioactive sphingolipid metabolite is now emerging as an important regulator of many physiological and disease processes of the immune, central nervous and cardiovascular systems. Most of the known actions of S1P are mediated by binding to five specific G protein-coupled receptors, designated S1PR1-S1PR5. While FTY720-P is an agonist at all of the S1PRs except S1PR2, its beneficial action in multiple sclerosis is generally believed to result from the induction of irreversible downregulation and degradation of S1PR1, a receptor that is critical for lymphocyte trafficking 1,2 . Decreased S1PR1 surface expression on activated T cells prevents their egress from lymphoid tissues and infiltration of autoaggressive lymphocytes into the CNS. Preclinical studies suggest that FTY720 accumulates and is phosphorylated in brain 3 and has beneficial effects in the CNS that are not understood yet, independent of its immune cell trafficking activity 1, 4 . S1P also has important intracellular actions 5, 6 . SphK2, which is present in the nucleus of many cells 5,7 , produces nuclear S1P that specifically binds to HDAC1 and HDAC2, inhibits their enzymatic activities and increases histone acetylation, linking nuclear S1P to epigenetic regulation of gene expression 5 . Yet it is still unknown whether nuclear SphK2 and S1P function similarly in vivo. HDAC1 and 2 belong to a large family of zinc-dependent HDACs, and HDAC inhibitors (HDACi) have long been used in psychiatry and various brain disorders and are being investigated as possible treatments for many diseases 8, 9 . Because SphK2 is the main SphK isoenzyme that phosphorylates FTY720 in vivo and FTY720-P is a close structural analog of S1P, we wondered where in the cell FTY720 is phosphorylated and whether it also mimics the intracellular actions of S1P and inhibits HDACs to regulate histone acetylation, gene expression and brain functions. RESULTS FTY720-P is generated in the nucleus by SphK2 and enhances histone acetylation FTY720 was rapidly taken up by human SH-SY5Y neuroblastoma cells. SphK2, which was predominantly found in the nucleus of these cells, as in many other types of cells, robustly phosphorylated FTY720, and hence FTY720-P accumulated over time to a greater level in the nucleus than in the cytoplasm (Fig. 1a-c) . There was much less secreted FTY720-P as compared to the intracellular pools in both primary hippocampal neurons (18 ± 3 as compared to 230 ± 32 pmol) and neuroblastoma cells (Fig. 1d) . Overexpression of SphK2, but not the catalytically inactive SphK2 G212E , increased formation of nuclear FTY720-P by >100-fold (Fig. 1e) , suggesting that nuclear SphK2 phosphorylates FTY720. The nucleus contains large amounts of sphingosine 5 , and overexpression of SphK2 also increased nuclear FTY720 (fingolimod), an FDA-approved drug for treatment of multiple sclerosis, has beneficial effects in the CNS that are not yet well understood, independent of its effects on immune cell trafficking. We show that FTY720 enters the nucleus, where it is phosphorylated by sphingosine kinase 2 (SphK2), and that nuclear FTY720-P binds and inhibits class I histone deacetylases (HDACs), enhancing specific histone acetylations. FTY720 is also phosphorylated in mice and accumulates in the brain, including the hippocampus, inhibits HDACs and enhances histone acetylation and gene expression programs associated with memory and learning, and rescues memory deficits independently of its immunosuppressive actions. Sphk2 −/− mice have lower levels of hippocampal sphingosine-1-phosphate, an endogenous HDAC inhibitor, and reduced histone acetylation, and display deficits in spatial memory and impaired contextual fear extinction. Thus, sphingosine-1-phosphate and SphK2 play specific roles in memory functions and FTY720 may be a useful adjuvant therapy to facilitate extinction of aversive memories. 
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We next examined whether FTY720-P produced in the nucleus by SphK2 mimics the nuclear actions of S1P. Treatment of SH-SY5Y cells with FTY720 increased acetylation of Lys9 of histone H3 (H3K9), Lys5 of histone H4 (H4K5) and Lys12 of histone H2B (H2BK12) (Fig. 2a) , the same residues that nuclear S1P increases 5 , without affecting acetylation of other lysines. Similarly, after treatment of hippocampal neurons with FTY720, nuclear FTY720-P gradually increased, concomitantly with an increase in histone H3K9 acetylation (Fig. 2b) . In accord with the increase in nuclear FTY720-P ( Fig. 1e and Supplementary Fig. 1a) , overexpression of SphK2, but not catalytically inactive SphK2 G212E , enhanced the effect of FTY720 on histone acetylation (Supplementary Fig. 1c) . To exclude the possibility that these effects were due to secreted FTY720-P that acts by binding to S1PRs on the plasma membrane, we examined the effects of FTY720-P on histone acetylation in highly purified nuclei, which do not contain S1PRs. Like addition of S1P 5 , addition of FTY720-P to isolated nuclei increased specific histone acetylations ( Fig. 2c and Supplementary Fig. 1d ). Moreover, histone acetylations induced by FTY720 itself added to isolated nuclei were prevented by downregulation of SphK2 (Fig. 2d) , which was associated with decreased nuclear formation of FTY720-P (326 ± 7 to 53 ± 8 pmol per mg protein). In contrast, treatment of cells with FTY720-P or S1P, which activates all of its receptors, as demonstrated by enhanced extracellular signal-regulated kinases (ERK1/2) phosphorylation, did not cause detectable changes in global histone acetylation ( Fig. 2e and Supplementary Fig. 1e ). Taken together, these results indicate that FTY720-P produced in the nucleus by SphK2 regulates specific histone acetylations independently of S1PRs.
FTY720-P, but not FTY720, potently inhibits class I HDACs
Histone acetylation levels are regulated by the opposing activities of histone acetyltransferases (HATs) and HDACs. Because FTY720-P has no effect on HAT activity (Supplementary Fig. 2 ), increased acetylation of histones could be due to direct inhibition of HDACs by FTY720-P, as we previously demonstrated that nuclear S1P has no effect on HAT activity but binds to and inhibits HDAC1 and 2 (ref. 5). Indeed, FTY720-P inhibited the activities of highly purified recombinant class I HDACs (HDAC1, HDAC2, HDAC3 and HDAC8) even more potently than S1P and almost as effectively as suberoylanilide hydroxamic acid (SAHA), a commonly used inhibitor of these HDACs ( Fig. 3a-d) . In contrast, FTY720 had no significant effects on activity of these class I HDACs. Even though S1P inhibited HDAC1-HDAC3, it did not inhibit HDAC8 activity (Fig. 3d) , and neither FTY720-P nor S1P inhibited the class II HDAC7 (Fig. 3e ).
FTY720-P binds to class I HDACs
To provide further evidence that FTY720-P targets class I HDACs, we examined whether FTY720-P binds to recombinant HDACs in a similar manner to that of S1P 5 . FTY720-P and dihydro-S1P, as well as SAHA, completely displaced bound [ 32 P]S1P from HDAC1 to the same extent as an excess of unlabeled S1P, indicating that they share a common or overlapping binding site (Fig. 4a) . In agreement with their inability to inhibit HDAC1 (Fig. 3 and ref. 5 ), neither FTY720 nor sphingosine competed with binding of [ 32 P]S1P to HDAC1, nor did lysophosphatidic acid (LPA), another bioactive lysophospholipid structurally related to S1P (Fig. 4a) . Moreover, [ 32 P]FTY720-P also specifically bound to recombinant HDAC1 and could only be displaced by excess FTY720-P, S1P, dihydro-S1P or SAHA (Fig. 4b) . Displacement curves indicated that both S1P and FTY720-P bound to HDAC1 with high affinities (Supplementary Fig. 3 ). FTY720-P bound to HDAC1 with an apparent K d of 6.2 nM, which is consistent with the half-maximal inhibitory concentration of ~25 nM for inhibition of HDAC1.
Next we sought to determine whether FTY720-P formed in the nucleus by SphK2 is bound to endogenous HDAC1. To this end, we treated cells with FTY720, isolated nuclei and measured FTY720-P and sphingolipids present in HDAC1 immunoprecipitates by mass spectrometry. In cells treated with FTY720, a substantial amount of FTY720-P was associated with HDAC1 immunoprecipitates, and Cytoplasmic (a) and nuclear (b) levels of FTY720 and FTY720-P were determined by liquid chromatography-electrospray injectiontandem mass spectroscopy (LC-ESI-MS/MS). (c) Equal amounts of protein were separated by SDS-PAGE and immunoblotted with SphK2-specific antibody. Antibodies against lamin A/C and tubulin were used as nuclear and cytosolic markers, respectively. (d) Total intracellular and secreted FTY720-P were determined by LC-ESI-MS/MS. *P < 0.001 as compared to medium; unpaired Student's t-test. (e,f) SH-SY5Y neuroblastoma cells transfected with vector, SphK2 or catalytically inactive SphK2 G212E (ciSphK2) constructs were treated without or with FTY720 for 6 h and nuclear levels of FTY720-P (e) and S1P (f) determined by LC-ESI-MS/MS. Equal expression was confirmed by immunoblotting. Data are expressed as mean ± s.d. *P < 0.005 as compared to vector; # P < 0.001 as compared to untreated; unpaired Student's t-test. All western blots were performed three times. Full-length blots are presented in Supplementary Figure 10 .
(g) Hippocampal neurons were treated with FTY720 for 1 h and nuclear levels of FTY720-P and S1P determined by LC-ESI-MS/MS (N = 3 independent cell culture replicates per group). Box plots indicate median (center line), 25-75th percentile (box limits), and minimum and maximum (whiskers). * npg a r t I C l e S HDAC active site consists of a tubular pocket with a zinc-binding site at the base, two aspartate-histidine charge-relay systems and a tyrosine that stabilizes the tetrahedral oxyanion necessary for catalysis 11 . The hydroxyl and amino groups of FTY720-P and S1P could act similarly to the hydroxamic acid of SAHA, which chelates the zinc atom, and may explain the mechanism of class I HDAC inhibition by FTY720-P and S1P. Molecular modeling also suggests that the highly conserved arginine stabilizes the phosphate group of S1P 5 and FTY720-P (Fig. 4d) and explains the low affinity of sphingosine and FTY720. Tyr303, important for catalysis, and His141 are also predicted to interact with S1P and FTY720-P ( Supplementary  Fig. 4 ). Another feature of the binding mode between FTY720-P and HDAC2 is that the phenyl ring of FTY720 could engage in π-π stacking with Phe206 and Phe151, which may increase the binding affinity. Lack of these distinctive features and the shallow binding pocket of HDAC7 may explain the lack of inhibitory effects of FTY720-P and S1P on HDAC7 (Fig. 3e) . Altogether, these data indicate that FTY720-P can bind to the active site of class I HDACs and inhibit their enzymatic activity. this amount was markedly increased by SphK2 overexpression (Fig. 4c) .
Generation of FTY720-P in the nucleus, which decreased formation of nuclear S1P, also reduced the amount of S1P bound to HDAC1 (Fig. 4c) . Molecular docking of FTY720-P to the active site of HDAC2 on the basis of the crystal structure 10 indicated that its binding mode is very similar to that of SAHA and S1P (Fig. 4d) . This conserved npg a r t I C l e S FTY720-P inhibits hippocampal HDACs, enhances histone acetylations, and facilitates fear extinction in SCID mice Recent studies suggest that FTY720 also has nonimmunological actions in experimental autoimmune encephalomyelitis and multiple sclerosis 1, 12 . FTY720-P accumulates in the brain and has beneficial effects that are not well understood in the CNS, independent of its immunosuppressive activity 1, 12 . Therefore, we next sought to examine the effects of FTY720 administration on HDAC activity and histone acetylation in vivo. As expected 1,13,14 , 24 h after oral administration of FTY720 to mice, circulating lymphocytes were significantly decreased, with a depletion of 85% at a dose of 0.5 mg per kilogram body weight, correlating with the increased serum levels of FTY720-P ( Supplementary Fig. 5a ,b). In accord with reports of brain accumulation of FTY720-P in rats 3 and humans 15 , FTY720-P accumulated in the brains of mice, including nuclei of hippocampal cells, in a dosedependent manner (Supplementary Fig. 5c ). Notably, FTY720 administration inhibited hippocampal HDAC activity ( Supplementary  Fig. 5d ) and also increased histone H3K9 acetylation, even at the lowest dose of FTY720 tested (Supplementary Fig. 5e ).
Chromatin remodeling, especially histone tail acetylation, has been implicated in memory formation, and pharmacological and mouse genetic approaches have demonstrated that HDACs influence memory and learning processes 8, 9 . Because we found that FTY720 is phosphorylated in the nucleus by SphK2 and that FTY720-P inhibits HDACs, we investigated whether, like other HDAC inhibitors [16] [17] [18] [19] [20] , it might also affect learning and memory in mice. However, because the immune system has complex effects on learning and memory, and to circumvent the known effects of FTY720-P on immunosuppression and lymphocyte trafficking, we decided to test its effects in severe combined immune deficient (SCID) mice, which are deficient in both T and B cell responses and substantially impaired in acquisition of the ability to perform cognitive tasks 21, 22 .
To examine the effects of FTY720 on learning and memory, SCID mice were administered daily oral FTY720 (1 mg/kg) or saline and exposed to a novel context, followed by electric footshock to elicit acquisition of hippocampus-dependent fear memory that was measured as percentage time freezing, defined as a lack of movement other than respiration. Saline-and FTY720-treated groups exhibited similar levels of freezing preshock, postshock and 48 h after conditioning (two-way repeated-measures ANOVA; interaction: F 2,26 = 0.05, P = 0.95; time: F 2,26 = 68.91, P < 0.0001; treatment: F 1,26 = 0.02, P = 0.90). Hence, FTY720 treatment did not alter the response to footshock, nor did it affect the acquisition of fear memories in these mice, as both groups displayed similar high levels of freezing (Fig. 5a ). These findings indicate that FTY720-treated mice did not forget the association between the context and footshock 48 h after conditioning.
Differential regulation of hippocampal histone acetylation has been shown to be important not only for memory acquisition but also for extinction of fear memories 17, 18, 23 . Fear extinction is a specific form of learning and is a mechanism for reducing excess fear of aversive events. Thus, we decided to test whether FTY720 treatment would affect contextual fear extinction. FTY720 (1 mg/kg) or saline was administered daily to the SCID mice, beginning 16 h before fear conditioning, followed by an extinction session and behavioral testing (Fig. 5a,b) . This is a clinically relevant dose and regimen that maintains therapeutic levels of FTY720 and FTY720-P in mice and humans 1, 24 .
During extinction training, the mice were reexposed to the conditioned stimulus (the context) without receiving the footshock again (extinction session, E1), which resulted in a decline in the freezing response. FTY720 and saline-treated SCID mice displayed comparable magnitudes of postshock freezing and freezing behavior upon exposure to the conditioning chamber 24 h after shock (two-way repeated-measures ANOVA; interaction: F 2,28 = 1.25, P = 0.30; postshock time: F 2,28 = 89.04, P < 0.0001; treatment: F 1,28 = 0.11, P = 0.75). Moreover, both groups had similar extinction rates during the 10-min acute extinction training session (two-way repeated measures ANOVA; interaction: F 3,42 = 1.40, P = 0.26; extinction time: F 3,42 = 15.85, P < 0.0001; treatment: F 1,42 = 0.08, P = 0.78). Remarkably, however, we observed marked differences on reexposure to the conditioning chamber 1 d later ( Fig. 5b; two-way repeated measures ANOVA; interaction: F 1,14 = 6.10, Figure 4 FTY720-P competes with S1P for binding to HDAC1. (a-c) Recombinant His-tagged HDAC1 immobilized to Ni-NTA resin or control Ni-NTA resin (control) was incubated with 0.1 nM [ 32 P]S1P (a) or 0.1 nM [ 32 P]FTY720-P (b) in the absence or presence of unlabeled 1 µM FTY720-P, FTY720, S1P, dihydro-S1P (DH-S1P), sphingosine, LPA or SAHA. Beads were washed extensively and [ 32 P]S1P or [ 32 P]FTY720-P bound to HDAC1 was eluted with 500 mM imidazole and radioactivity detected by scintillation counting. (c) Nuclear extracts from HeLa cells transfected with vector or SphK2 and treated without or with FTY720 (5 µM) for 4 h were immunoprecipitated with anti-HDAC1 antibody or control immunoglobulin G, and bound sphingolipids and FTY720-P determined by LC-ESI-MS/MS. Data are averages of triplicate determinations ±s.d. *P < 0.0001 as compared to none (a,b) or untreated (c) and # P < 0.0001 as compared to vector (unpaired Student's t-test) (N = 3 independent cell cultures per group). (d) Docking of FTY720-P into the pocket of HDAC2. The low-energy conformations of FTY720-P, S1P and SAHA were calculated when docked in a model based on the crystal structure of HDAC2 (Protein Data Bank: 3MAX). Left, surface contour of the binding site with S1P, SAHA and FTY720-P. The surface contour is colored by electrostatic potential. Right, the binding of S1P (magenta), SAHA (yellow) and FTY720-P (cyan) with HDAC2. The active site residues involved in the interactions with small molecules are shown as sticks and the zinc atom as a sphere. npg a r t I C l e S P = 0.03; treatment: F 1,14 = 12.04, P = 0.004; day: F 1,14 = 29.50, P < 0.0001). FTY720-treated mice maintained low levels of freezing behavior during the consolidation test (day 3) (P = 0.008; Bonferroni post hoc test), indicating that extinction was preserved, whereas the saline-treated SCID mice, as expected 25 , displayed a marked deficit in extinction memory as manifested by elevated freezing (Fig. 5b) . These data reveal that FTY720 rescues extinction deficits in SCID mice. FTY720-P also accumulated in various brain areas of SCID mice, including the hippocampus (Fig. 5c and Supplementary Fig. 6 ), an area of the brain important for learning and memory, at much higher levels than in serum. Hippocampal S1P and dihydro-S1P were slightly decreased after FTY720 treatment (Fig. 5c) . As in C57BL/6 mice ( Supplementary Fig. 5d ), treatment of SCID mice with FTY720 reduced hippocampal HDAC activity by 50% without discernible differences in expression of HDAC1, 2, 3 or 8 (Fig. 5d) . Nevertheless, FTY720 administration also enhanced acetylation of specific histone lysine residues in the hippocampus (Fig. 5d) , particularly H3K9, H4K12 and H4K5, associated with regulation of memory processes 26, 27 . npg a r t I C l e S Additional groups of SCID mice were trained in the Morris water maze (MWM) task, a hippocampus-dependent spatial memory test. In agreement with others, we found that SCID mice performed very poorly in the MWM 21, 22 , and treatment with FTY720 did not affect their performance (ref. 28 and Supplementary Fig. 7a-c) . Like treatment with other HDAC inhibitors 19, 27 , treatment with FTY720 did not affect exploratory behavior in a novel environment or basal anxiety-like behavior (Supplementary Fig. 7d-f) , nor tonedependent fear conditioning that is hippocampus independent, nor did it affect extinction of response to the tone conditioned stimulus (Supplementary Fig. 7g) . Altogether, these data indicate that FTY720 protected the SCID mice from deficits in expression of extinction in the contextual fear model. This aspect of learning is important for the organism to reduce fear-related behavior in response to a stimulus that no longer predicts an aversive event.
Hippocampal memory-related gene expression We next examined whether the effects of FTY720 on histone acetylation correlated with changes in specific hippocampal programs of gene expression. One hour after the consolidation test, we isolated hippocampal RNA and analyzed the hippocampal transcriptome. This revealed that 475 genes (216 upregulated and 259 downregulated) were differentially expressed in FTY720-treated SCID mice as compared to the control saline-treated group. Bioinformatic analysis indicated that many of the differentially expressed genes were specifically linked to learning-regulated genes (Supplementary Table 1) , and 280 have been implicated in processes important for spatial and motor learning, cognition and memory (Fig. 5e) . Functional over-representation analysis with both Ingenuity and TOPPGene identified gene networks related to neuroplasticity, associative learning and behavior. Quantitative PCR analysis verified a significant increase in expression of Vegfd (also known as Figf), recently shown to be involved in cognitive function 29 , and decreased expression of the transcription factor Tcf4 (Fig. 5f) , a schizophrenia risk gene 30 whose upregulation in mice correlates with reduced cognitive performance 31 . Expression of several HDAC-regulated memory-associated genes, including Fos (cFos), Gria1 (also known as Glur1) and nuclear receptor subfamily 4, group A, member 2 (Nr4a2) 19, 32 , was also increased in the hippocampus of FTY720-treated mice (Fig. 5f) .
Our attention was drawn to VEGFD because it is also a cFos-induced growth factor 33 , and cFos, an immediate-early gene and transcription factor, is regulated by SphK2 and nuclear S1P 5 . In accord with its effect on histone acetylation (Supplementary Fig. 5e ), Vegfd expression was increased 6-to 7-fold 24 h after treatment of C57BL/6 mice with FTY720 (Supplementary Fig. 5f ). Expression of brain-derived neurotrophic factor (Bdnf) was also significantly increased (P < 0.01), albeit to a lesser extent (Supplementary Fig. 5g ). Owing to its short half-life, Fos mRNA expression was transiently increased much earlier, whereas Vegfd expression remained sustained (Supplementary Fig. 5h,i) .
We next sought to determine whether the increased pattern of specific gene expression correlated with increased synaptic plasticity. To this end, we assessed the effect of FTY720 on long-term potentiation (LTP) of the Schaffer collateral input to CA1, which forms excitatory synapses on pyramidal cells in the stratum radiatum, by electrophysiological recordings. LTP was induced using 100 Hz trains patterned as theta bursts, a stimulation protocol known to induce long-lasting, transcription-dependent LTP 23, 34 . As in previous results with HDAC inhibitors 19, 23, 26, 35, 36 , we found that pretreatment of hippocampal slices with FTY720, which was phosphorylated to FTY720-P, did not affect baseline stimulus-response curves or paired-pulse facilitation (Fig. 6a,b,d) . In contrast, like other HDAC inhibitors 19, 23, 26, 35, 36 , FTY720 treatment significantly facilitated LTP (Fig. 6c) . Hence, treatment with FTY720 enhances synaptic plasticity but does not affect basal synaptic transmission.
Sphk2 -/-mice have reduced hippocampal histone acetylation and learning deficits Because SphK2, not SphK1, is the main isoform in the brain and is highly expressed in hippocampus 37, 38 , we used Sphk2 −/− mice to examine the function of SphK2-produced S1P in the regulation of hippocampal HDAC activity and histone acetylation in learning and memory models. Sphk2 −/− mice had significantly less S1P and dihydro-S1P in the hippocampus than wild type (WT) (Fig. 7a) . In contrast to its effect in the colon 39 , ablation of SphK2 was not accompanied by compensatory upregulation of SphK1 in the hippocampus (Fig. 7a) . Deletion of SphK2 also significantly decreased hippocampal histone acetylation on specific lysine residues (H3K9, H4K5, a r t I C l e S H4K12) (Fig. 7b) that are linked to memory impairment 26, 27 . There were, however, no discernible differences in brain anatomy, suggesting that absence of SphK2 is not detrimental to brain development. Next we evaluted these mice on the MWM. In the fixed-platform test, mice learn the location of a hidden platform using distal visual cues. Both WT and Sphk2 −/− mice found the platform faster as training proceeded, with no impairment in Sphk2 −/− mice (two-way, repeated-measures ANOVA; interaction: F 9,171 = 0.96, P = 0.48; day: F 9,171 = 21.58, P < 0.0001; genotype: F 1,171 = 1.22, P = 0.28) (Fig. 7c) . After 10 d of fixed-platform training, we conducted a probe trial in which we removed the hidden platform and measured the time spent in each quadrant of the water maze. Sphk2 −/− mice did not show a spatial preference for the target quadrant, whereas the WT littermates spent significantly more time in the target quadrant (Fig. 7d) (twoway, repeated-measures ANOVA; genotype × quadrant interaction: F 3,57 = 5.96; P = 0.0013; Bonferroni post hoc test: P < 0.001 for WT versus knockout mice in the target quadrant), suggesting that Sphk2 −/− mice have spatial memory deficits in the MWM task. Both genotypes displayed similar swim speeds (Fig. 7e) and identical performance in the visible-platform test (Fig. 7f-h) , indicating that gross sensorimotor and/or motivational deficits are unlikely to account for the poor performance of Sphk2 −/− mice during the probe trial.
We then evaluated the mice in a contextual fear conditioning task that included assessment of extinction. There were no significant differences in acquisition of fear memories between Sphk2 −/− and WT mice (Fig. 8a and Supplementary Fig. 8a) , and magnitudes of postshock freezing and freezing behaviors were comparable upon reexposure to the conditioning chamber 48 h (Supplementary Fig. 8a ) or 96 h (Fig. 8a) after shock (two-way, repeated-measures ANOVA; interaction: F 2,34 = 2.36, P = 0.11; time: F 2,34 = 151, P < 0.0001; genotype: F 1,34 = 1.83, P = 0.19). Both genotypes displayed significant increases in freezing behavior (P < 0.001, Bonferroni post hoc) as compared with preshock freezing levels, indicating that memory for the context and footshock even 96 h after conditioning was not disrupted by the gene deletion. Moreover, both genotypes had similar extinction rates during the 10-min extinction training session, E1, when reexposed to the novel context without a shock (Supplementary Fig. 8b ). However, after repeated reexposure to the conditioned context on subsequent days (24-h intervals) without receiving the footshock again (extinction trials E2-E4), WT and Sphk2 −/− mice displayed significant differences in extinction of contextual fear memory (Fig. 8b) (two-way ANOVA; genotype × day interaction: F 3,48 = 1.40, P = 0.25; genotype: F 1,48 = 8.06, P = 0.01; day: F 3,48 = 19.60, P < 0.0001). While freezing behavior in the WT group declined during further extinction training (P < 0.05 for days 3-5, Bonferroni post hoc test), Sphk2 −/− mice showed elevated freezing throughout the extinction sessions (Fig. 8b) . Of note, impaired expression of extinction exhibited by Sphk2 −/− mice was not rescued by FTY720 administration (two-way, repeated measures ANOVA; treatment × day interaction: F 3,54 = 2.51, P = 0.07; treatment: F 1,54 = 0.13, P = 0.72; day: F 3,54 = 27.66, P < 0.0001). This finding is consistent with the notion that SphK2 is the main isoform in the brain that phosphorylates FTY720 to its active form (ref. 1 and Fig. 8c) . The impairment of fear extinction of the Sphk2 −/− mice was not due to decreased initial fear responses or locomotor activity, because reaction to shock during the training session ( Fig. 8a and  Supplementary Fig. 8a) , as well as exploratory and basal anxietylike behaviors, were virtually identical between the two genotypes ( Supplementary Fig. 9a-d) . Moreover, freezing in response to toneconditioned stimulus also did not differ between the Sphk2 −/− and WT mice (Supplementary Fig. 9e) .
Because SphK2 knockout mice showed a deficit in extinction of contextual fear memories that correlated with lack of inhibition of npg a r t I C l e S HDACs as a result of decreased levels of nuclear S1P, the only known endogenous inhibitor of HDAC 5 , and decreased histone acetylations, we examined whether treatment of these mice with the potent HDAC inhibitor SAHA would rescue the memory deficit. Indeed, SAHA administered to SphK2 knockout mice reversed the increased HDAC activity (Fig. 8d) and reinstated hippocampal histone acetylations (Fig. 8e) . Notably, SAHA treatment facilitated expression of fear extinction in Sphk2 −/− mice ( Fig. 8f) (two-way repeated measures ANOVA: treatment × day interaction: F 2,28 = 6.75, P = 0.004), and SAHA-treated Sphk2 −/− mice displayed a significant decrease in freezing on day 4 (P < 0.05; Bonferroni post hoc test) as compared to those treated with vehicle. These data reveal that SAHA can rescue extinction deficits in Sphk2 −/− mice.
DISCUSSION
Our study has uncovered a new mechanism of action of the prodrug FTY720 and revealed that FTY720 enters the nucleus, where it is phosphorylated by SphK2. In turn, FTY720-P that accumulates there binds and inhibits class I histone deacetylases (HDACs) and consequently enhances specific histone acetylations independently of S1PRs. We demonstrated this with recombinant HDACs, in neuronal cell culture, and in vivo. In mice, this enhances acetylation of histone lysine residues linked to epigenetic regulation of learning and memory genes and facilitates fear extinction independently of its established effect on lymphocyte trafficking. Another noteworthy aspect of the actions of FTY720 is that, in spite of the facilitation of contextual fear extinction in SCID mice, it had no effect on spatial memory performance in the MWM, which depends on both visual and motor functions. This could be a consequence of different requirements and structures underlying these forms of learning. Moreover, mice may use multiple behavioral tactics to escape from the water, and some of these strategies may be comparably efficient but distinct in their requirement for hippocampal function 35 .
Systemic or intrahippocampal administration of HDACi facilitates fear extinction in mice [16] [17] [18] 23, 40 , increases synaptic plasticity, enhances long-term memory 19, 20 and improves memory function in aging mice 27 and in mouse models of neurodegenerative disorders 9, 41 . Nevertheless, several HDAC inhibitors also enhance acquisition of conditioned fear memories, and some of these compounds are potentially toxic or brain impermeant and cannot be administered to humans. In contrast, we have demonstrated that FTY720, which readily penetrates the CNS of rodents 3 and humans 15 , is converted to FTY720-P, inhibits HDACs in the hippocampus, enhances LTP in hippocampal neurons and facilitates extinction of aversive memories without enhancing fear memory acquisition. Owing to these distinctive features, FTY720 might be more effective than other HDAC inhibitors as an adjuvant therapy for eliminating aversive memories. Enhancing extinction of fear memory is of great interest for treatment of anxiety disorders, such as post-traumatic stress disorder 42 . It is possible that development of similar analogs of sphingosine and FTY720 that can be phosphorylated by SphK2 to a mimetic of S1P that retains its nuclear actions but lacks immunomodulatory effects on S1PRs might be useful for extinguishing fear memories.
Our studies suggested that the enhancement of contextual fear extinction by FTY720 did not globally alter gene expression but involved epigenetic regulation of transcription of certain genes that are essential for behavior and long-term synaptic plasticity and memory. Especially intriguing is the upregulation of the growth factors VEGFD and BDNF. VEGFD controls maintenance of dendrite arborization in the adult mouse hippocampus in an Figure 8 SAHA administration to SphK2 knockout mice reversed the increased HDAC activity, reinstated hippocampal histone acetylations and rescued their extinction deficit in contextual fear conditioning. (a) Deletion of SphK2 has no effect on contextual fear conditioning. Top, experimental design. Sphk2 −/− and WT mice were fear conditioned (FC) with three footshocks. Preshock, postshock and 96-h (day 5) freezing were evaluated, with no extinction session. *P < 0.001 as compared to preshock. N = 9 mice per group. (b) Sphk2 −/− mice display deficits in contextual fear extinction that are not rescued by FTY720. WT and Sphk2 −/− mice were treated daily with saline or FTY720 (1 mg/kg) as indicated. Mice were fear conditioned with three footshocks on day 1 and received daily 10-min extinction sessions in the conditioning chamber without footshocks on days 2-5. Fear extinction consolidation on the indicated days was determined during the first 2.5 min of the extinction session. # P < 0.05 versus E1 (day 2). *P < 0.05 between WT and Sphk2 −/− mice (Bonferroni post hoc test). N = 8 WT mice, 10 Sphk2 -/-mice. (c) Accumulation of FTY720 and FTY720-P in hippocampus from the WT and Sphk2 −/− mice was measured by LC-ESI-MS/MS. *P < 0.05 between WT and Sphk2 −/− mice. N = 5 mice. (d-f) SAHA rescues histone acetylation and extinction of fear memories in Sphk2 −/− mice. Sphk2 −/− mice were injected intraperitoneally with vehicle or SAHA (25 mg/kg) daily starting 10 d before behavior testing 26 . (f) Mice were then exposed to contextual fear conditioning and tested 24 h later. Extinction of contextual fear was performed on consecutive days, as described above, and fear extinction on the indicated days was determined during the first 2.5 min of the extinction session. # P < 0.05 versus E1 (day 2). *P < 0.05 versus Sphk2 −/− mice treated with vehicle (Bonferroni post hoc test). N = 7 vehicle-treated and 9 SAHA-treated mice. Data represent means ± s.e.m. Hippocampi were isolated 1 h after the last consolidation test and HDAC activity in hippocampal nuclear extracts determined with a fluorometric assay (d; *P < 0.001, unpaired Student's t-test) and histone acetylations examined by immunoblotting with the indicated antibodies (e; *P < 0.05 as compared to vehicle, unpaired t-test). Quantified data are expressed as mean ± s.e.m. H3 was used as an internal loading control. SAHA npg a r t I C l e S autocrine manner and is required for cognitive function and memory formation 29 . Thus, the large increase in hippocampal expression of VEGFD in mice might contribute to memory enhancement upon FTY720 administration. Like HDACi 16 , and in agreement with other findings 43 , FTY720 also enhanced expression of BDNF, a neurotrophin involved in synaptic plasticity processes that are required for long-term memory 16, 44 . Although in cortical neurons FTY720-P mediates increased BDNF by ERK1/2 signaling downstream of S1PR activation 43 , it is not known whether the increased BDNF expression in a mouse model of Rett syndrome after 4 weeks of FTY720 administration involves S1PRs 43 or, as we suggest here, is due to its intracellular actions. Of relevance, in animals that successfully extinguished fear, endogenous BDNF was elevated only in the hippocampus, and infusion of BDNF into hippocampus reduced fear even in the absence of extinction training but did not disrupt performance or the fear memory itself 44 . These results might be related to the impairment of extinction in both mice and humans by a BDNF polymorphism 45 . Expression of the orphan nuclear receptor Nr4a2, a HDAC-and CREB-dependent gene that has been implicated in long-term memory 19 , was also increased following the memory-enhancing effect of FTY720. In this regard, long-term memory enhancement by hippocampusspecific HDAC3 deletion or inhibition is abolished by intrahippocampal delivery of Nr4a2 short interfering RNA 32 , suggesting that negative regulation of memory formation by HDAC3 requires Nr4a2. Moreover, blocking hippocampal Nr4a2 transcriptional activity impairs long-term memory but does not affect short-term memory, and it prevents memory enhancement by HDACi 46 . Thus, Nr4a target genes may contribute to memory enhancement by FTY720. Notably, a recent study reported that a selective inhibitor of class I HDACs epigenetically primes the expression of neuroplasticity-related genes (for example, Fos) to overcome the resilience of remote fear memories to successful extinction 23 .
Another related observation in our study was that Sphk2 −/− mice, which had decreased levels of S1P in the hippocampus, displayed reduced histone acetylation and had impaired spatial memory and contextual fear extinction. The lack of inhibition of HDACs associated with decreased levels of nuclear S1P in Sphk2 −/− mice could be overcome by treatment with a potent inhibitor of HDACs, which also reinstated hippocampal histone acetylation and the contextual fear extinction deficits. However, a caveat of these studies is that they do not conclusively demonstrate that these deficits are due to the loss of SphK2. Although Sphk2 −/− mice showed impaired fear extinction, memory acquisition was not altered. Extinction is an active mnemonic process that has some similarity with other steps of memory formation, yet increasing evidence now suggests that distinct pathways are involved in acquisition and extinction of fear memories 41, [47] [48] [49] . Our data suggest that the SphK2-S1P-HDAC axis is important in epigenetic regulation of expression of genes mediating extinction of aversive memories and that targeting specific hippocampal HDACs with compounds such as FTY720 deserves consideration as an adjuvant therapy for post-traumatic stress disorder and other anxiety disorders.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. GEO: microarray data, GSE57015. 
ONLINE METHODS
cell culture and transfection. Hippocampal neurons were cultured from embryonic day 18 C57BL/6 mouse embryos as described 50 . Briefly, the hippocampus was dissected free from the rest of the brain, minced, and incubated for 30 min at 37 °C with trypsin and DNase in Neurobasal medium (Invitrogen) supplemented with B-27 additives (Invitrogen), l-glutamine (0.5 mM), glutamate (25 µM) and an antibiotic mixture. Tissue was triturated, resuspended in medium, filtered twice through 70-µm-pore nylon mesh, then plated in Neurobasal medium. The cultures were almost exclusively neurons as assessed by neuronal nuclear (NeuN) or microtubule-associated protein 2 (MAP2) immunostaining; glial contamination at time of use in experiments was less than 2%. For western blot analyses, 2 × 10 6 cells were plated per well in six-well plates coated with poly-llysine. Human neuroblastoma SH-SY5Y and HeLa cells (ATCC) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% (vol/vol) serum. Cells were transfected with vector, SphK2 or catalytically inactive SphK2 G212E constructs or with ON-TARGETplus SMARTpool siRNA against SphK2 (5′-CAAGGCAGCUCUACACUCA-3′; 5′-GAGACGGGCUGCUCCAUGA-3′; 5′-GCUCCUCCAUGGCGAGUUU-3′; 5′-CCACUGCCCUCACCUGUCU-3′) and control siRNA from Dharmacon as previously described 5 .
nuclear extracts. Cells were washed with cold PBS and resuspended in buffer containing 10 mM HEPES (pH 7.8), 10 mM KCl, 0.1 mM EDTA, 1 mM Na 3 VO 4 , 1 mM DTT, 1:500 protease inhibitors (Sigma), and incubated on ice for 15 min. NP-40 was added to 0.75% (vol/vol) and cells were vortexed for 10 s. Nuclei and supernatant ("cytoplasm") were separated by centrifugation at 1,000g for 3 min at 4 °C. Nuclei were resuspended in buffer containing 20 mM HEPES (pH 7.8), 0.4 M NaCl, 1 mM EDTA, 1 mM Na 3 VO 4 , 1 mM DTT and 1:500 protease inhibitors and incubated on ice for 15 min. Nuclear extracts were cleared by centrifugation at 14,000g for 5 min at 4 °C.
HdAc activity measurements. HDAC activity of purified recombinant His6-tagged HDAC1-HDAC3, HDAC8 and HDAC7 purified from Sf9 cells was determined with a fluorometric HDAC activity assay as described 5 . Reaction mixtures containing Boc-Lys(Ac)-AMC as substrate were incubated at 37 °C for 30 min, lysine developer was added and the mixture was then incubated for 30 min at 37 °C. Fluorescence was measured with excitation at 360 nm and emission at 460 nm. No-enzyme controls and inhibitor controls were included. S1P and FTY720-P binding assays. Recombinant His6-tagged HDAC1 was incubated with [ 32 P]S1P or [ 32 P]FTY720-P (0.1 nM, 6.8 µCi/pmol) in buffer containing 50 mM Tris (pH 7.5), 137 mM NaCl, 1 mM MgCl2, 2.7 mM KCl, 15 mM NaF and 0.5 mM NaV 3 O 4 for 25 min at 30 °C. His 6 -tagged protein was then immobilized on Ni-NTA resin and washed three times with the same buffer to remove unbound proteins, and bound proteins were eluted with 500 mM imidazole. S1P or FTY720-P associated with the eluted proteins was quantified with a LS6500 scintillation counter (Beckman). Where indicated, unlabeled S1P, DH-S1P, sphingosine, FTY720-P, FTY720, LPA or SAHA (Enzo) were added 10 min before addition of the labeled compounds.
HAT activity. HAT activity in nuclear extracts was determined using a colorimetric assay kit (Abcam) in which free CoA produced serves as a coenzyme for NADH production that is detected spectrophotometrically (440 nm) upon reacting with a soluble tetrazolium dye, as described previously 5 . mass spectrometry measurements. Lipids were extracted. Phosphorylated and unphosphorylated sphingoid bases, FTY720 and FTY720-P were quantified by liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS, 4000 QTRAP, AB Sciex) as described 39 .
Immunoblotting. Equal amounts of protein were separated by SDS-PAGE, transblotted to nitrocellulose and incubated with primary antibodies. The antibodies used were as follows: rabbit polyclonal antibodies to histone H4 (07-108), H2B (07-371), H3K23ac (07-355), H3K18ac (07-354) and H4K16ac (07-329) (Millipore, 1:1,000 dilution); histone H3 (ab24834), H3K9ac (ab10812), H4K5ac (ab51997) and H2BK12ac (ab61228) (Abcam, 1:1,000 dilution); H4K12ac (2591), lamin a/c (2032), tubulin (2145), p-ERK1/2 (4372), HDAC3 (3949) and HDAC7 (2882) (Cell Signaling, 1:1,000 dilution); HDAC1 (sc-7872), HDAC2 (sc-7899) and HDAC8 (sc-11405) (Santa Cruz Biotechnology, 1:1,000 dilution); V5 (R960-25, Invitrogen, 1:5,000 dilution). Immunopositive bands were visualized by enhanced chemiluminescence using secondary antibodies conjugated with horseradish peroxidase (goat anti-rabbit (111-035-045, 1:5,000) and goat anti-mouse (115-035-166, 1:10,000), Jackson ImmunoResearch Laboratories) and Super-Signal West Pico chemiluminescent substrate (Pierce). Blots were not stripped and reprobed. Optical densities of bands associated with proteins of interest were quantified using AlphaEaseFC software (Alpha Innotech) and normalized to the optical densities of their respective H3 bands.
mice. Male SCID mice (CB17-Prkdc scid /J) were purchased from the Jackson Laboratory. C57BL/6 wild-type and Sphk2 −/− mice were from R. Proia (NIH). Three-month-old male mice with littermate controls to assure the same genetic background were used for all experiments. Animal procedures were approved by the Institutional Animal Care and Use Committee at Virginia Commonwealth University. FTY720 administration. Mice were treated daily by oral administration of 1 mg/kg FTY720 in saline, unless indicated otherwise, by gavage. FTY720 was administered 16 h before fear conditioning and behavioral assessments.
SAHA administration. Suberoylanilide hydroxamic acid (SAHA, vorinostat) was dissolved in DMSO at a concentration of 50 mg/ml and then diluted to 5 mg/ml in saline just before injection. Mice received intraperitoneal injections daily with SAHA (25 mg/kg) or vehicle starting 10 d before memory tests and were alternated daily between left and right sides of the abdomen, always 16 h before testing as described 26 .
contextual fear extinction test. To measure associative learning, contextual fear conditioning was used as described previously with minor modifications 51 . The training consisted of a single exposure to the novel experimental chamber (47.5 × 41 × 22 cm) for 2.5 min followed by three electric foot shocks (0.70 mA; 30 s ITI (intertrial interval)). Baseline freezing behavior was measured in the 2.5 min before the shock was administered and postshock freezing evaluated for 30 s after the third shock. Mice were then returned to their home cages. Contextdependent freezing, a conditioned fear-related response, was assessed 24 h later in the first 2.5-min bin. Mice were assessed for extinction by giving them a 10-min exposure to the conditioned context without footshock, which results in a decline of the time spent freezing. On subsequent days, mice were evaluated in a 2.5-min consolidation test to determine whether freezing behavior was still extinguished. ANY-maze video tracking system and software (Stoelting) was used to track the mice and analyze immobility.
Tone-paired conditioned fear test and extinction. Mice were assessed in tone-paired conditioned fear as previously described 52 . Mice were placed in an olfactory-paired, transparent, Plexiglas experimental chamber (47.5 × 41 × 22 cm) with the shock floor in place. After a 3-min acclimation period, a 20-s tone (80 dB) was presented that coterminated with a scrambled 2-s (0.7 mA, alternating current) electric foot shock. SCID mice received five tone-shock pairings. Mice were returned to their home cage 1 min later. On successive days, mice underwent extinction training in a different experimental chamber that was paired with a new olfactory cue and lacked shock grids. During extinction sessions, mice were placed in the novel chamber for a 180-s acclimation period, presented with the tone for 200 s, and removed 60 s later from the apparatus and returned to their respective home cages. In the conditioning session, percentage of time spent freezing was assessed 180 s before tone-shock pairings (preshock) and 60 s after tone-shock pairings (postshock). In each extinction session, the percentage of time spent freezing during the 200-s tone was determined.
exploratory behavior and basal anxiety tests. Mice were placed in a plastic arena (47.5 × 41 × 22 cm). The exploratory behavior of the animals, distance traveled during the first 3 min of the test and thigmotaxia time, defined as time spent less than 5 cm away from the wall of the apparatus, were determined using ANY-maze video tracking and software. Light/dark testing used a small (36 × 10 × 34 cm) enclosed, dark box with a passageway (6 × 6 cm) leading to a larger (36 × 21 × 34 cm), light box. Before testing, mice were acclimated in the testing room for 1 h. Mice were then placed in the light side of the box and allowed to npg freely explore the apparatus for 5 min. Time spent in the light and dark sides was measured by ANY-maze software. The marble-burying test was carried out in a polycarbonate cage (33 × 21 × 19 cm) filled to a depth of 5 cm with pine wood bedding. Before testing, 20 clear, glass marbles (10 mm diameter) were arranged in an evenly spaced, grid-like fashion across the surface of the bedding and the cages were placed in a lit, sound-attenuated chamber. Mice were placed in the cage, which was then covered with a transparent, Plexiglas lid with air holes, and assessed for 20 min. The number of marbles buried (defined as 50% or more of the marbles covered by bedding) was counted by a trained observer. considered significant. Electrophysiological results were evaluated using mixedmodel ANOVAs, with treatment as a between-subjects variable and time after HFS or interpulse interval as repeated measures.
A Supplementary methods checklist is available.
